In this task, you're given a paragraph from the research paper and your task is to generate a suitable title for the research paper based on the given paper. Under 100 words is a good title length.

An immunochromatographic test strip (ICTS) for detecting antibodies to rabies virus was developed, using colloidal gold particles labeled with rabies virus glycoprotein as the tracer. The assay was evaluated using sera from dogs immunized with various commercial rabies vaccines, or from dogs in the clinics and sera from dogs immunized with vaccines against pathogens other than rabies virus, and negative sera from a wide variety of animal sources, including dogs, mice, and cats which had never been vaccinated. The ICTS was found to be highly specific for antibodies against rabies virus, with a detection limit of 0.5 IU/ml as measured by the fluorescent antibody virus neutralization (FAVN) test. Compared with the FAVN test, the specificity and sensitivity of ICTS were 98.2% and 90.4%, respectively. There was an excellent agreement between results obtained by the ICTS and FAVN tests (kappa = 0.888). Strips stored at 4 • C in a plastic bag with a desiccant retained their specificity and sensitivity for at least 15 months, and strips stored at ambient temperature remained stable for 12 months. The immunochromatographic test strip may therefore be useful for clinical laboratories lacking specialized equipment and for diagnosis in the field for rapid detection of rabies virus-specific antibodies.
A rapid immunochromatographic test strip for detecting rabies virus antibody

Background/Aims: Interferon and ribavirin combination therapy for chronic hepatitis C induces a low response rate in human immunodeficiency virus (HIV) infected patients. To assess the impact of intensification of interferon administration and of the addition of amantadine on the efficacy and safety of standard anti-hepatitis C virus (HCV) treatment in HIV-infected patients. Methods: Multicentre, prospective, open-label, randomized, phase III clinical trial. Eighty co-infected patients were randomized to receive ribavirin 800 -1000 mg/day in combination with, group A: interferon alpha2a 3 MIU thrice weekly; group B: IFNa2a 3 MIU daily, plus amantadine 200 mg/day; treatment duration was 24 -48 weeks according to HCV genotype. Results: Forty-one patients were randomized in group A and 39 in group B. Intention-to-treat analysis showed a sustained virological response, defined as HCV-RNA negativization, 6 months after stopping treatment in 22% of patients from group A and 13% from group B (P > 0.05). The lack of a 2-log drop in HCV-RNA levels after 12 weeks of treatment showed a 100% predictive value of lack of sustained response. Conclusions: Amantadine addition and interferon intensification do not improve the low efficacy of combination of interferon alfa plus ribavirin in HIV/HCV co-infected patients. Patients with no early virologic response did not have any probability of sustained response. q
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients q

The primary objective of this panel discussion was to seek input on the following 3 questions from the speakers at the workshop. Comments and questions were also entertained from the members of the audience. Question 1: Considering the potential advantages of microbial decontamination of indoor air, what criteria should be used to select a given technology? Dr C. Duchaine: Technologies of interest will depend on the situation and the point source of microbial contamination, for example, a person coughing in an emergency room, a patient vomiting in a hospital ward, or a student vomiting in a classroom. The intervention of choice must be relevant for the site, for instance, a hospital versus a shopping mall. Portable indoor air decontamination devices may be used in smaller areas, such as classrooms, but devices that would allow global decontamination (eg, at a hospital or a shopping mall) would be more challenging. When possible, routine and continuous air treatment may be better than an on-site intervention. Dr Y. Li: Technologies that are effective for decontamination of circulating air in different situations would be more desirable. One example is the use of UVGI in air circulation ducts if the potentially generated ozone can be effectively removed to avoid its entry into occupied zones. The technology of choice must be safe when people are present, while also being energy efficient. Further, it must not only be effective, but also scalable to suit the site of use. The results of testing in an aerobiology chamber can be much different than those in a large area, such as a hospital or a large shopping mall, where there are on-going changes in the air quality parameters. The debate continues as to whether indoor air for breathing should be treated in the same fashion as water for drinking.

Workshop on "The Role of Indoor Air as a Vehicle for Human Pathogens": A Panel Discussion